ProCE Banner Activity

BRUIN CLL-321: Phase III Trial of Pirtobrutinib vs Idelalisib + Rituximab or Bendamustine + Rituximab in Covalent BTK Inhibitor–Pretreated CLL/SLL

Conference Coverage
Slideset

In the randomized phase III BRUIN CLL-321 trial in patients with CLL/SLL previously treated with a covalent BTK inhibitor, pirtobrutinib was associated with a significant progression-free survival benefit compared with idelalisib/rituximab or bendamustine/rituximab.

Released: December 11, 2024

Expiration: December 10, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation